abrdn Life Sciences Investors
Veridion Score
Composite trend over time
Why is HQL moving today?
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for HQL.
HQL insider activity
abrdn Life Sciences Investors
No multi-insider buying cluster in the last 90 days
Net selling: -$2.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-18 | 2025-12-16 | Pittard Christian | Insider | buy | $16.88 | 7,923 | 7,923 | $134K | SEC Form 4 |
| 2025-09-23 | 2025-09-22 | Saba Capital Management, L.P. | Insider | sell | $14.14 | 41,623 | 2,837,633 | $589K | SEC Form 4 |
| 2025-09-23 | 2025-09-19 | Saba Capital Management, L.P. | Insider | sell | $14.10 | 6,989 | 2,879,256 | $99K | SEC Form 4 |
| 2025-09-19 | 2025-09-18 | Saba Capital Management, L.P. | Insider | sell | $14.07 | 40,208 | 2,886,245 | $566K | SEC Form 4 |
| 2025-09-19 | 2025-09-17 | Saba Capital Management, L.P. | Insider | sell | $13.99 | 24,328 | 2,926,453 | $340K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 7 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moHQL contract awards, year to date.
Public federal awards linked to this ticker.
HQL lobbying filings, year to date.
Registered lobbying filings matched to abrdn Life Sciences Investors.